NVCR - Novocure Ltd
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
NovoCure Limited is downgraded from Strong Buy to Buy after the phase 3 TRIDENT trial failed to meet its primary endpoint of OS in newly diagnosed GBM patients. Company maintains growth potential with positive phase 2 PANOVA-4 results in mPDAC, ongoing KEYNOTE D58 trial in GBM, and an upcoming FDA decision for NSCLC brain metastases in Q4 2026. Q1 2026 net revenues rose 12% to $174 million, driven by Optune Gio, with full-year 2026 revenue guidance raised to $690–$710 million.
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
NVCR secures European approval for Optune Pax, expanding access to its pancreatic cancer treatment after strong late-stage trial results.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 23, to discuss the company's financial results for the three-month period that ended June 30, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access.
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Optune Pax® has received CE (Conformité Européenne) Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations. “Pancreatic cancer is often diagnosed in late stages when tumors are more difficult to treat. As a result, treatment options have limited effect and survival.
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.
[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure L
LOS ANGELES--(BUSINESS WIRE)---- $NVCR--NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm.
Amgen delivers robust cash flow and high net margins through its established portfolio of blockbuster medications. NovoCure offers a unique direct-to-patient model for tumor treatment, targeting niche oncology markets with tumor-treating electrical fields.
Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday on June 18, 2026.
Novocure said on Thursday that its cancer treatment for newly diagnosed brain tumors did not meet the main goal of a late-stage study.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced topline results today from its Phase 3 TRIDENT trial, which evaluated the initiation of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM) at the start of chemoradiation (Early Start Arm) compared to initiating TTFields therapy during the subsequent maintenance phase of treatment (Maintenance Start Arm). The trial did not demonstrate a statistically significant improvement in the primary endpoint.
This oncology device innovator, known for its tumor-treating technologies, reported a notable insider sale in its latest SEC filing.